DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/4xw677/acute_spinal_cord) has announced the addition of GlobalData's new report "Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.

Pharmaceutical Research into Spinal Cord Injuries Will Stretch into Next Decade

Drugs under development to treat those affected by acute spinal cord injuries are not expected to emerge within the current decade, leaving the market largely open to new entrants, according to a new report issued by pharmaceuticals intelligence provider GlobalData.

The new report* shows that there have been no treatment options approved for Acute Spinal Cord Injury (ASCI) by either the Food and Drug Administration (FDA) or the European Medicines Agency (EMA), so off-label generic drugs dominate the market.

Spinal Cord Injury (SCI) refers to damage to the spinal cord which results in the loss of mobility and feeling. SCI usually occurs due to a sudden traumatic blow to the spine that fractures or dislocates vertebrae, caused by injuries involving the head, pelvic fractures, penetrating injuries close to the spine, or injuries caused by a fall from a significant height. The classification of SCI into acute and chronic phases is based on the period of time the patient has suffered with the condition.

In USA, Methylprednisolone Sodium Succinate (MPSS) is prescribed as off-label drug used for treating inflammation in ASCI, acting to reduce swelling in the spinal cord. However, it is also associated with certain adverse effects, such as reduced immunity, infections and gastrointestinal bleeding, among others. This has led European physicians to prescribe other off-label drugs instead, including anticoagulants, proton pump inhibitors, antihypotensives, antidiabetic, Gamma Aminobutyric Acid (GABA) analogs and antibiotics. However, all these medications have their limitations in treating ASCI.

The absence of effective treatment options clearly signifies that current competition in the ASCI therapeutics market is weak. Therefore, significant opportunity exists for novel products that can provide better treatment, and lead to better recovery from injury.

Companies Mentioned

- Asubio Pharmaceuticals, Inc.

See the original post here:
Research and Markets: Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Comments are closed.